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Objectives: The observational, non-interventional EDGE study showed that a DPP-4 
inhibitor, vildagliptin, is efficacious in patients with type 2 diabetes mellitus who 
have suboptimal glycaemic control on metformin monotherapy in the real-life set-
ting, confirming the results of previous randomised clinical trials. We sought to 
perform a health economic evaluation using using patient level data (PLD) from 
EDGE using an established diabetes outcomes model. MethOds: The IMS Core 
Diabetes Model (CDM) was used to evaluate the lifetime costs and quality adjusted 
life expectancy (QALE) of two different regimens: metformin+vildagliptin compared 
to metformin+sulphonylurea (SU). Annual therapy costs were: £106.79 (year 1), then 
£110.51 (year 2+) for metformin+SU and £410.53 (year 1), then £412 (year 2+) for 
metformin+vildagliptin. Therapy escalation at HbA1c of 8.5% was modelled assum-
ing insulin glargine+metformin (cost £899.51 year 1; £806.84 year 2+). Published 
meta-analysis data were used for hypoglycaemia rates. Multivariate regression 
analysis of PLD output from CDM was undertaken using R version 2.15.2. UK costs 
(£GBP) and health benefits were discounted at 3.5%. Results: Mean discounted 
QALE was 11.01 years (SD 2.5). QALE decreased with increasing age (-0.19 per year, 
p< 0.001) and (-0.18 per year, p< 0.001) for metformin+SU and metformin+vildagliptin 
regimens, respectively. Increasing diabetes duration was associated with a greater 
decrease in QALE with metformin+SU (-0.18 per year, p< 0.001) compared to 
metformin+vildagliptin (-0.08 per year, p< 0.001). Each unit increase in baseline 
BMI was associated with a -0.12 decrease in QALE for metformin+SU (p< 0.001), 
with no significant difference observed in the metformin+vildagliptin regimen. 
After adjustment metformin+vildagliptin was associated with a £595.30 reduction 
in overall costs compared to metformin+SU. cOnclusiOns: The statistical analy-
sis of PLD output provides a mechanism for identifying greatest potential health 
gains. Despite being positive in all patients, gains in QALE were greater in patients 
with longer diabetes duration and metformin+vildagliptin regimen compared with 
metformin+SU under a real-life setting.
PRM112
SuRgeRy AS An OutcOMe In cOSt-effectIveneSS AnAlySIS
Murphy D, Vlachaki I, Guy H
WG Access Ltd, London, UK
Objectives: Surgery in cost-effectiveness analysis can lead to counter-intui-
tive results, with patients whose disease progresses faster undergoing surgery 
sooner. As surgery typically results in improved quality of life (QoL) following 
intervention surgery can have a beneficial impact on ICERs for less successful 
treatment, in spite of a patient preference to avoid surgery. This study under-
took a targeted review of previous NICE technology appraisals in order to assess 
the impact that surgery has had on decision making in the UK. MethOds: 
A sample of NICE technology appraisals were reviewed to identify papers 
that have included surgery in their modelled clinical pathways. Key model 
inputs, results and the impact of surgery on model results were extracted for 
each study. Results: Two technology appraisals were identified that incor-
porated surgery as a clinical outcome. In TA297, surgery had minimal influ-
ence on model results. With both low incidence and no substantial impact of 
surgery on QoL. In TA329, utility values associated with surgery were 0.7 com-
pared with pre-surgery values ranging from 0.41 to 0.87. Immediate colectomy 
was found to dominate all non-surgical strategies. If immediate colectomy was 
excluded as a treatment option, no novel treatments would be cost-effective 
against conventional care in spite of this being the least effective treatment. 
Whilst a number of factors contribute to the overall result, the impact of surgery 
should be quantified. cOnclusiOns: Surgery can have a counter intuitive influ-
ence on model results, with a negative event having a long-term positive impact 
on patient QoL. From this review a number of factors have been found to influence 
the magnitude of this impact. These include health state utilities before and after 
surgery, and timing of surgery. Decision rules are required that ensure that surgery 
is properly accounted for when making decisions, factoring in higher surgical rates 
into decision making may partly address this issue.
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Objectives: The Timed Automata modeling paradigm has emerged from 
Computer Science as a mature tool for the functional analysis and performance 
evaluation of timed distributed systems. This study is a first exploration of the 
suitability of Timed Automata for health economic modeling, using a case study 
on personalized treatment for metastatic Castration Resistant Prostate Cancer 
(mCRPC). MethOds: The treatment process has been modeled by creating several 
independent timed automata, where an automaton represents a patient, a physi-
cian, a test, or a treatment/testing guideline schedule. These automata interact 
via message passing and are fully parameterized with quantitative information. 
Messages can be passed, asynchronously, from one automaton to one or more 
other automata, at any point in time, thereby triggering events and decisions in the 
treatment process. In the automata time is continuous, and both QALYs and costs 
can be incorporated using (assignable) local clocks. Uncertainty can be modeled 
using probabilities and timing intervals that can be uniformly or exponentially 
distributed. Software for building timed automata is freely available for academic 
use and includes procedures for statistical model checking (SMC) to validate the 
(internal) behavior and results of the model. Results: In several days a Timed 
Automata model has been produced that is compositional, easy to understand 
and easy to update. The behavior and results of the model have been assessed 
using the SMC tool. Actual results for the mCRPC case study obtained from the 
Timed Automata model are compared with results of a Discrete Event Simulation 
model in a separate study. cOnclusiOns: The Timed Automata paradigm can be 
successfully applied to evaluate the potential benefits of a personalized treatment 
process of mCRPC. The compositional nature of the resulting model provides a 
i.e. ARAMIS and CEPAC, for cost-effectiveness analysis in Russia is not possible due 
to differences in the disease classifications and lack of statistical data. The purpose 
of this work was the modeling of HIV progression in Russian HIV-infected popula-
tion. MethOds: We develop the Markov model based on transitions through four 
mutually exclusive health states defined by CD4+ cell count ranges (> 500, 351–500, 
201–350, and < 200 cells/ml) and death and baseline characteristics of high prognostic 
value, such as viral load, age, sex, and antiretroviral treatment receiving. To iden-
tify the model’s parameters we used state statistics and publications of the Russian 
Federal Research Centre for Prevention and Control of AIDS. In order to validate 
model we calculated life expectancy after diagnosis using Monte-Carlo simulation 
of treated and non-treated cohorts. To study the influence of treatment on life expec-
tancy we used the 1st line regimen abacavir + zidovudine + lamivudine + enfuvir-
tide. Results: Life expectancy of treated patients is significantly higher compared 
to patients who did not receive treatment (medians and quartiles 24.6 [22.6; 26.5] 
and 13.8 years [12.7; 14.4] years, respectively, P< 0,001, Mann-Whitney U-test). These 
results acceptably correspond to the results of cohort studies and clinical trials. Life 
expectancy is significantly lower for men than for women both with and without 
treatment. cOnclusiOns: The results of modeling conform the real data from the 
Russian population. The model is currently being finalized to calculate QALY, ICER, 
and others.
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veRIfIcAtIOn And vAlIdAtIOn Of heAlth ecOnOMIc MOdelS fOR 
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Objectives: Published ISPOR guidelines indicate that new economic models should 
be subjected to through internal testing and debugging. Moreover, evidence that this 
has been done should be provided. Currently there are few published examples 
of such internal validation work. The aim of the present analysis was to perform 
verification and validation analyses of a novel model for Type 1 Diabetes (the PRIME 
Diabetes Model). MethOds: Source code (Java) for the T1D PRIME Diabetes Model 
was delivered to an independent third party. Program code was reviewed for syntax 
errors and tested via a separate software environment. This process included using 
null and extreme input values to test whether the expected outputs were produced. 
Replication tests using equivalent endpoint values were also performed. Verification 
queries were resolved by discussion and the findings of the analysis were described 
in a report. Results: Internal validation confirmed all numbers and formulas col-
lected from the literature and examined whether they were correctly implemented 
in the source code. Face validity was established with regard to the model’s struc-
ture, use of available clinical evidence, problem formulation and results. Given that 
the PRIME Diabetes Model is programmed in Java, MATLAB was used to validate 
model components independently and results were tested at patient mean levels 
as well as the corner cases of minimum and maximum values in order to ensure 
the model produced valid results over the entire range of patient characteristics. 
The model passed both internal and face and validity reviews. cOnclusiOns: 
Published verification analyses in line with ISPOR guidance for all new health 
economic models would improve transparency and provide a valuable resource for 
health care decision makers. Using the PRIME Diabetes Model, the present analysis 
provides a real-world example of how verification and validation analyses can be 
performed and reported.
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IMPAct Of POveRty On MultIdIMenSIOnAl InfAnt MORtAlIty RAte In 
bRAzIl
Araujo JA1, Silva AF1, Wichmann R2
1Federal University of Ceará, Fortaleza, Brazil, 2Brazilian Ministry of Health, Brasília, Brazil
Objectives: The infant mortality rate is considered an important general indicator 
both of health conditions as the living conditions and development of a population. 
By presenting certain sensitivity to various external factors, this rate is directly related 
to economic and social characteristics. It’s understood that high infant mortality rates 
are associated with the needs of socioeconomic conditions. Thus, the factors influenc-
ing poverty levels (one-dimensional and multidimensional) on Infant Mortality Rate 
in Brazil are investigated in this paper. MethOds: So it was considered, in addition 
to analyzing the impact of one-dimensional poverty, which measures poverty only by 
per capita income, the impact of multidimensional poverty, whose definition incor-
porates other dimensions, such as sanitation, housing, information, among others. In 
order to delineate the models, variables such as per capita income, the Gini index and 
education level were employed for the Brazilian states from 2001 to 2011. Four models 
were developed to analyze both individually and together impacts of the explanatory 
variables on the infant mortality rate. For this purpose, panel data was used on fixed 
and random effects. Results: The results showed that decrease the concentration 
of income and increased educational level, in that order, were the variables which 
most contributed to the reduction of infant mortality over the period considered. In 
all, the one-dimensional and multidimensional poverty rates contributed significantly 
to the reduction of infant mortality rate. However, the ratio of multidimensional 
poor impact showed a three times higher than the proportion of one-dimensional 
poor. cOnclusiOns: The findings indicate that it is essential to the formulation of 
public policies to reduce income concentration allied to improvements in educational 
conditions, and reduction of multidimensional poverty rates in order to tackle the 
problems of poor health, and thus reduce the rate of infant mortality.
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modeling, event based microsimulation/patient level simulation. Health outcomes 
included survival, number-needed-to-treat, life expectancy, and quality-adjusted life 
years, time horizon and cycle length. All the studies were critically appraised using 
quality of health economic scale (QHES) and were found to be of moderate to high 
quality. Evaluated therapeutic strategies comprised chemotherapeutic combina-
tion therapies, stem cell transplantation and supportive care. cOnclusiOns: Our 
review provides a comprehensive overview of modeling studies assessing treatment 
of DLBCL which could be used by researchers to develop novel models in DLBCL.
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Objectives: Multiple-criteria decision analysis (MCDA) is a sub-discipline of opera-
tions research that explicitly considers multiple criteria in decision-making envi-
ronments. Formally structuring complex problems appropriately and considering 
multiple criteria explicitly leads to more informed and transparent decisions. MCDA 
methods are increasing in popularity, however existing instruments and approaches 
are rigid and do not reflect local decision making needs and preferences. ZRx MCDM 
was developed as a highly flexible tool to support the application of local multiple-
criteria decision analysis in health care. This tool was used to evaluate, as an example, 
three alternatives for the management of anemia associated with chronic kidney 
disease: Procrit, Aranesp and a Biosimliar (Epogen Zeta). MethOds: There are mul-
tiple MCDA standard methods that can be applied and the ZRx MCDM tool has been 
validated against the publications of such methods. Users enter desirable data by 
selecting an appropriate number of alternatives and criteria relevant to particular 
decision-making context. Further, criteria scale and weights are defined to obtain 
results (alternatives in sequence of importance) per different MCDA calculation 
methods. Seven local decision-makers applied inter-criteria weights using visual 
analogue scale (VAS). Results: Applying the Simple Linear Adaptive Model (SLAM) 
method, the decision-making criteria as ranked in order of importance were safety, 
budget impact, cost-effectiveness and unmet medical need (equal third), patient 
preferences and strategic considerations. Global scores calculated for Aranesp were 
marginally higher than for the biosimilar (0.52 vs 0.51), whereas Procrit (0.46) scored 
lower. When Multi Attribute Value Theory (MAVT) method was further applied, total 
score differentiation was more pronounced: Aranesp, Biosimilar and Procrit (0.57, 0.50 
and 0.46). cOnclusiOns: ZRx MCDM tool has been successfully applied in a local 
decision making context. By not relying on, or promoting, pre-defined criteria, level 
definitions and weighting/aggregation methods, the tool is fully flexible and adaptive 
to high precision local decision making needs and preferences.
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PAtent exPIRy And geneRIc PRIcIng: the IMPAct On cOSt- effectIveneSS 
ReSultS
Hirst A, Murphy D, Vlachaki I
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Objectives: Several studies have considered the change in the price of medicines 
once a medicines patent expires and exclusivity in the market place is lost. Some 
HTA bodies consider the implications of patent expiry (e.g. PHARMAC) however the 
potential impact is not considered in the NICE reference case. The aim of this study 
was to consider how including the costs of medicines after patent expiry could impact 
cost-effectiveness results. MethOds: A targeted review was conducted to identify 
any studies which had considered the impact of patent expiry. The approaches were 
compared and contrasted. A review of recent treatments that have received negative 
reimbursement decisions from HTA bodies were considered to determine if generic 
pricing could have influenced the decision making process. Results: Patent expiry 
has potential to impact results, however only in a handful of selected disease areas. 
The assumptions required to implement generic pricing after patent expiry can be 
associated with considerable uncertainty, particularly around the generic price of 
medicine. Further to this, the impact that generic pricing has is dependent on both 
duration of treatment and life expectancy of modelled populations. cOnclusiOns: 
Patent expiry offers manufactures a chance to reduce the cost associated with treat-
ment without altering health outcomes. However this is likely to offer a comparable 
discount to a majority of comparators available in the market, therefore it is likely this 
will offer the biggest benefit to the manufactures that implement it first.
PRM120
MOdel-bASed technIqueS In the eARly PhASeS Of the MedIcAl devIce 
develOPMent: A SySteMAtIc lIteRAtuRe RevIew
Manetti S, Turchetti G
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Objectives: To systematically review the existing applications of the early 
model-based techniques to innovative biomedical devices under development. 
Furthermore, our purpose is to identify their usefulness, limitations, potential 
improvements, impact on primary stakeholders and implications. Even though the 
early Health Technology Assessment (HTA) of new medical devices is recognized 
as an integral part of the technology production, many methodological criticali-
ties still afflict this field. The high level of uncertainty, connected with the scar-
city and heterogeneity of data, needs to be faced readjusting the mainstream HTA 
methodology to support both medical technology producers and policy makers 
alongside with the R&D process. MethOds: Published studies in the English lan-
guage, related to period 2000-2015, were searched using computerized databases 
(Pubmed, Scopus, ScienceDirect, Web of Science, IEE Xplore) and reference search 
of the included articles. All papers that applied the health economic modeling to 
R&D medical devices met our inclusion criteria. Given the immaturity of the field, 
we also examined conference proceedings that met the same criteria. Results: 
good separation of all relevant components. This leads to models that are easy to 
formulate, validate, understand, maintain and update.
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Objectives: Schizophrenia is a persistent and costly disease, which requires a 
continuous antipsychotic treatment. In antipsychotic treatment of schizophrenia, 
the differences in terms of effectiveness, tolerance, incidence of side effects, relapse 
and costs have implications regarding the cost-effectiveness. The objective of the 
specialistic research is to investigate the cost-effectiveness of two second generation 
antipsychotics (SGA) in treatment of patients with schizophrenia in the RS health-
care system. MethOds: The Markov model was developed to assess the medical 
cost-effectiveness of olanzapine and risperidone (SGA) in relation to haloperidol 
(FGA) .The cohorts of patients were adult patients diagnosed with schizophrenia . 
Transitional probabilities were taken over from a major meta-analysis conducted 
by NICE. The cost considered in this model were taken over from list of rates Health 
insurance fund (HIF). The utility (in QALY) for remission or relapse were taken over 
from a scale published by Lenart et al. The cost-effectiveness measure was the 
Incremental cost-utility ratio (ICUR) . The set threshold was 3200 EUR. Results: 
Undiscounted results of the basic cost-effectiveness analysis show ICUR for olan-
zapine= 912EUR/QALY, ICUR for risperidone = 1528 EUR/QALY. Discounted results 
show ICUR for olanzapine = 877EUR/QALY, ICUR for risperidone= 1502 EUR/QALY. 
Sensitivity analysis has shown , in case of increase in transition probability for 
relapse by 10%, olanzapine remains a cost-effective strategy, whereas risperidone 
becomes a cost-ineffective strategy. The sensitivity analysis has also shown the 
stability of the basic analysis results. cOnclusiOns: No strategy showed itself as 
dominant, both alternative strategies having higher costs but also higher effective-
ness. The model showed that, it takes less money for a better quality in olanzapine 
than risperidone strategy, while in relation to the set threshold both strategies were 
cost-effective. Both olanzapine and risperidone have proven cost-effective strategies 
from the HIF perspective with the recommendation that olanzapine should also be 
included in the reimbursement list .
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Objectives: To systematically review and assess the quality of model-based eco-
nomic evaluations concerning chemotherapy and targeted therapy for metastatic 
breast cancer (MBC). To analyse the impact of different modelling characteristics on 
the outcomes of these studies. MethOds: The search was performed in PubMED and 
NHS EED. Inclusion criteria were: English or Dutch language, model-based economic 
evaluation, chemotherapy or targeted therapy as intervention, population diagnosed 
with MBC, published between 2000 and October 2014, reporting life-years (LY) or 
quality-adjusted life year (QALY), and reporting an incremental cost-effectiveness 
ratio (ICER). Quality of the studies was assessed through a checklist. A standardised 
extraction sheet was used to retrieve general characteristics, modelling character-
istics and results of the studies. Results: Twenty-six studies were included and 
provided fifty-two comparisons. Eighteen studies used a health state-transition model 
including the following health states: stable/progression-free disease, progression 
and death. Subgroup analyses were conducted in three studies. Studies were of poor 
quality. Administration frequency of the regimens, type of model, perspective of the 
analysis, elicitation method for utilities, total amount of QALY gained and funding 
source were not always reported. Incremental LY and incremental QALY (iQALY) var-
ied from 0.06 to 1.52 and from 0.05 to 0.60, respectively. Mean incremental cost was 
€ 18,977 (range: € -10,690 - € 84,174). Mean ICER per LY and per QALY gained were € 12,000 
(range: € 200 - € 64,000) and € 76,000 (range: € 300 - € 625,000), respectively. Seven com-
parisons were represented in two or three studies and were used to analyse the effect 
of modelling characteristics on the iQALY estimates. cOnclusiOns: The results of 
the studies were highly variable and the quality of the studies was poor. Comparison 
of studies was hampered because of under-reporting and the limited number of stud-
ies comparing the same regimens. Consequently, no firm conclusions could be drawn 
concerning the effect of modelling characteristics on outcomes.
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Objectives: Diffuse large B-cell lymphoma (DLBCL) is the most common form 
of NHL, accounting for up to 30 percent of newly diagnosed cases in the United 
States and Europe. The purpose of this study was to provide a clinician-friendly 
landscape of decision-analytic models evaluating different treatment strategies 
for DLBCL. MethOds: A comprehensive search strategy was developed and a sys-
tematic literature search in Pubmed and EMBASE from 1996 to June 1, 2015 was 
queried to identify studies evaluating DLBCL treatment strategies using various 
decision-analytic models. Studies were screened using pre-defined inclusion criteria 
after which data from included trials were extracted, by two independent review-
ers and disagreements resolved by a third reviewer. We included studies that were 
published as full-text articles in English, and assessed relevant clinical endpoints, 
and summarized methodological characteristics (e.g., modeling approaches, simula-
tion techniques, health outcomes, perspectives). Results: Seven decision-analytic 
modeling studies met our inclusion criteria out of the total 289 citations. Major mod-
eling approaches adopted were: decision-tree modeling, Markov state-transition 
